Lonza Launches Media Development Lab in Singapore for Cell Culture Media Optimisation
March 26, 2026 – BioManufacturing, Biotechnology, Drug Discovery, Other, Pharmaceutical – CDMO, GMP manufacturing, Lonza, bioprocessing, cell culture production, media development lab, site opening
- New media development services designed to optimize cell culture media development and identify robust, scalable media formulations driving cell culture performance and reliability
- The offering is designed to improve performance, reduce risk, and help ensure smooth scale-up into manufacturing
- The service has been offered at Lonza’s Singapore (SG) site since March.
26 March 2026 — Basel, Switzerland — Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), today announced the launch of its Media Development Lab at its Singapore site. The offering aims to support bioprocessing customers in optimizing their media formulations and facilitating a smooth transition to GMP manufacturing, helping reduce scale-up risk and strengthening long-term supply readiness.
As development timelines accelerate and process complexity increases, the cost and risk associated with late-stage reformulation and scale-up continue to rise. Many organizations still lack structured media optimization and alignment between development and manufacturing.
To address these challenges, the Media Development Lab provides a systematic approach to early media optimization while accounting for scalability, raw material readiness, and GMP manufacturability. Leveraging Design of Experiments, the service evaluates multiple variables simultaneously to identify key performance drivers, accelerating development timelines, and reducing unnecessary iterations. It combines access to Lonza’s proprietary, diverse media and feed libraries with manufacturability insights to identify robust, scalable formulations early in development, with structured outputs that define performance ranges and process robustness.
Michael Goetter, Head of Bioscience, Specialized Modalities, Lonza, commented: “We are committed to providing customers with the services they need to reduce early-stage risk and select media formulations that are effective at a laboratory scale and simultaneously practical and reliable in manufacturing. Our new Media Development Lab enables us to support customers at the critical front end of their programs, shape formulation strategy, and create a natural pathway into non-GMP and GMP manufacturing.”
For more information on Lonza’s Media Development Lab, please visit Custom media and buffer solutions | Lonza
About Lonza
Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry. We work alongside a broad range of customers – from emerging biotechs to global pharmaceutical companies – to transform their therapeutic discoveries into life-saving and life-enhancing treatments for their patients. Our vision is to be the pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology and lean manufacturing. Founded in 1897 in the Swiss Alps, our business has embraced innovation and kept pace with a fast-changing world for more than 125 years. As the first and the original CDMO, we have been manufacturing medicines for more than four decades. Today we offer one of the largest Western CDMO networks with a global team of approximately 20,000 colleagues working across more than 30 sites in five continents. Our people are united by a common purpose: to turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Discover more about our One Lonza strategy here. Our business is structured to meet our customers’ complex needs across three synergistic Business Platforms: Integrated Biologics, Advanced Synthesis and Specialized Modalities. Our services span from early development to drug substance and drug product manufacturing, and we lead in both established and emerging technologies including mammalian biologics, small molecules, highly potent active pharmaceutical ingredients (APIs), bioconjugates, mRNA, microbial, and cell and gene. Across technologies, we deliver integrated solutions to meet our customers’ needs throughout the entire treatment lifecycle. Our company generated sales of CHF 6.5 billion with a CORE EBITDA of CHF 2.1 billion in Full-Year 2025. Lonza shares are listed on the SIX Swiss Exchange and Swiss Market Index (SMI), with a secondary listing on the SGX Singapore Exchange. Visit: www.lonza.com.
